Daily digest — 2026-10-25

A 58% cut in death risk against Imfinzi alone, in a 563-patient trial, makes tarlatamab plus durvalumab a credible new first-line maintenance standard in SCLC, a setting with few advances. Pairing with AstraZeneca's PD-L1 incumbent also moves Imdelltra from later-line use toward earlier lines, where its commercial ceiling is far higher. Tolerability and the exact survival figures will decide how fast adoption follows.

A full clinical hold lifted on the strength of one extra safety study with no cardiac events is a fast reversal, but it still leaves ARD-101 a year from restarting. Next year's resumption means Aardvark's Prader-Willi timeline slipped materially. The detail to watch is how regulators want cardiac monitoring built into the restart; the summary is silent on that.

Two safety events in roughly two months is a pattern investors and regulators will not ignore: a pause in late summer, now a patient death in MS. Moving CAR-T from oncology into autoimmune disease means asking patients with manageable conditions to accept lymphodepletion risk, so the tolerability bar is far higher. Details are thin, but BMS's disclosure ahead of the Breakfree-2 data looks like deliberate risk management.

Eight tumor types responding is a breadth signal, but without response rates, sample sizes or durability, it reads as a platform teaser, not a registrational case. The sharper hook is activity after checkpoint failure, where unmet need is large and a T cell agonist can differentiate from PD-1 combinations. Expect Marengo to need a partner or financing, and to narrow to one or two lead indications.

Two exits in one year, a Vega sale to Incyte worth up to $2B plus an Electra IPO, make Star look less like a single-asset biotech and more like a repeatable company-creation engine. The $200M round is investors paying for that process, not a lead molecule. The risk is that preclinical hematology and immunology biologics are still unproven, and the summary gives no program detail.

A 10-point fall from 92% to 82% is what happens when a small early cohort meets a larger one, and 82% in pancreatic cancer is still extraordinary. Tango's real leverage is that its MTAP-deleted PRMT5 play rides on Revolution Medicines' newly approved Rasonque, giving a small biotech a de-risked partner backbone into Phase 3. Durability, not response rate, will decide this.

The licensing carve-out is the part that matters: China-sourced assets remain buyable, so the in-licensing pipeline that big pharma has leaned on likely keeps running. What gets squeezed is US equity capital, which could push Chinese biotechs toward Hong Kong, domestic or Middle Eastern funding. Details are still thin, so scope and definitions will decide the real impact.

A $165M crossover in May followed by an F-1 five months later is the classic window-testing playbook, and Windward is betting investors will pay for China-sourced ex-China rights without the discount once attached to them. Sourcing from Kelun-Biotech, Harbour BioMed and Qyuns gives it a cheap, fast pipeline, but little proprietary edge beyond execution; the in-house R&D pitch is how it tries to change that.

A 2027 filing target despite a lukewarm readout suggests AbbVie sees lutikizumab as a pipeline-refill play, not a breakout. Hidradenitis suppurativa is crowded with established IL-17 options, so hitting endpoints without clearly beating them leaves differentiation thin. With Humira erosion ongoing, AbbVie likely values a dermatology follow-on even at modest peak sales.

A near-miss on one of two analyses is a weak footing for a first-in-class Lyme vaccine, and it hands regulators room to ask hard questions. Pfizer carries the commercial risk alongside Valneva, so the filing path and label breadth now matter more than the headline efficacy. Details are thin, so treat any launch timing as unsettled.